You just read:

Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia andSmall Lymphocytic Lymphoma

News provided by

Tolero Pharmaceuticals, Inc.

Jun 12, 2019, 08:00 ET